Can analysts adopt a bullish outlook for Indivior PLC (LON:INDV)?

October 13, 2017 - By reb123z

 Can analysts adopt a bullish outlook for Indivior PLC (LON:INDV)?

Indivior PLC (LON:INDV) Ratings Coverage

Among 8 analysts covering Indivior Plc (LON:INDV), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Indivior Plc had 98 analyst reports since July 29, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Indivior PLC (LON:INDV) rating on Tuesday, April 4. Stifel Nicolaus has “Buy” rating and GBX 500 target. Numis Securities maintained Indivior PLC (LON:INDV) rating on Friday, July 29. Numis Securities has “Buy” rating and GBX 340 target. RBC Capital Markets maintained the shares of INDV in report on Thursday, August 3 with “Outperform” rating. The firm has “Buy” rating by Jefferies given on Friday, April 29. Numis Securities maintained the shares of INDV in report on Wednesday, February 22 with “Buy” rating. The firm has “Buy” rating by Deutsche Bank given on Thursday, February 23. Deutsche Bank maintained Indivior PLC (LON:INDV) on Thursday, August 18 with “Buy” rating. Stifel Nicolaus maintained Indivior PLC (LON:INDV) on Thursday, December 10 with “Buy” rating. The firm has “Buy” rating given on Wednesday, June 7 by Jefferies. The rating was maintained by Deutsche Bank with “Buy” on Monday, June 6. Below is a list of Indivior PLC (LON:INDV) latest ratings and price target changes.

08/09/2017 Broker: Jefferies Rating: Buy Old Target: GBX 540.00 New Target: GBX 358.00 Maintain
05/09/2017 Broker: Citigroup Rating: Neutral Old Target: GBX 280.00 New Target: GBX 280.00 Maintain
01/09/2017 Broker: Numis Securities Rating: Buy New Target: GBX 470.00 Maintain
11/08/2017 Broker: Jefferies Rating: Buy Old Target: GBX 490.00 New Target: GBX 540.00 Maintain
03/08/2017 Broker: RBC Capital Markets Rating: Outperform New Target: GBX 470.00 Maintain
28/07/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: GBX 390.00 New Target: GBX 470.00 Upgrade
27/07/2017 Broker: Numis Securities Rating: Buy New Target: GBX 490.00 Maintain
11/07/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
07/06/2017 Broker: Jefferies Rating: Buy Old Target: GBX 490.00 New Target: GBX 490.00 Maintain
31/05/2017 Broker: Numis Securities Rating: Buy New Target: GBX 490.00 Maintain

The stock decreased 1.00% or GBX 3.42 on October 13, reaching GBX 337.68. About 1.20M shares traded. Indivior PLC (LON:INDV) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Indivior PLC is a specialty pharmaceutical company. The company has market cap of 2.43 billion GBP. The Firm is engaged in the development, manufacture and sale of buprenorphine prescription drugs for the treatment of opioid dependence (the Indivior Business). It has a 47.73 P/E ratio. The Company’s treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

More notable recent Indivior PLC (LON:INDV) news were published by: Prnewswire.com which released: “Indivior PLC Announces FDA Acceptance with Priority Review Designation of RBP …” on July 31, 2017, also Seekingalpha.com with their article: “Indivior Could Fall Further Once Generic Suboxone Arrives” published on September 12, 2017, Prnewswire.com published: “Indivior PLC Presents Results from the Phase 3 Pivotal Study of RBP-6000 …” on June 21, 2017. More interesting news about Indivior PLC (LON:INDV) were released by: Seekingalpha.com and their article: “Indivior Treads Forward In Opioid Addiction Market” published on June 06, 2017 as well as Prnewswire.com‘s news article titled: “DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement” with publication date: October 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: